Liver Cancer
Conditions
Brief summary
Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for patients with surgically unresectable hepatocellular carcinoma.
Detailed description
To compare between combination treatment with radiofrequency or microwave ablation followed by transarterial chemoembolization and performed in a single session.
Interventions
TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
PROCEDURERadiofrequency ablation combined with TACE
Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
PROCEDUREMicrowave ablation combined with TACE
Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
Sponsors
Tanta University
Sherief Abd-Elsalam
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Child classification A or B. * serum albumin ≥ 3 gm/L. * serum bilirubin \< 2.5 mg/dL. * platelet count ≥70,000 mm3. * INR ≤ 1.6. * serum creatinine \< 2 mg/dl. * tumor size more than 4 cm and confined to one lobe of the liver.
Exclusion criteria
* Patients with portal vein thrombosis. * A technically inaccessible hepatic artery. * Metastatic HCC. * More than three lesions. * lesions in close proximity to the portal vein (PV),inferior vena cava (IVC) or gall bladder were excluded from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with successful ablation | 3 months | The total number of patients with successful ablation |
Countries
Egypt
Contacts
Primary ContactSherief M. Abd-Elsalam, Consultant
Outcome results
None listed